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ABSTRACT
p53, a transcription factor that participates in multiple cellular functions, is 
considered the most important tumor suppressor. Previous evidence suggests that 
post-transcriptional deregulation of p53 by microRNAs contributes to tumorigenesis, 
tumor progression and therapeutic resistance. In the present study, we found that 
the microRNA miR-766 was aberrantly expressed in breast cancer, and that over-
expression of miR-766 caused accumulation of wild-type p53 protein in multiple cancer 
cell lines. Supporting its role in the p53 signalling pathway, miR-766 decreased cell 
proliferation and colony formation in several cancer cell lines, and cell cycle analyses 
revealed that miR-766 causes G2 arrest. At a mechanistic level, we demonstrate 
that miR-766 enhances p53 signalling by directly targeting MDM4, an oncogene and 
negative regulator of p53. Analysis of clinical genomic data from multiple cancer 
types supports the relevance of miR-766 in p53 signalling. Collectively, our study 
demonstrates that miR-766 can function as a novel tumor suppressor by enhancing 
p53 signalling.
INTRODUCTION
p53 is a nuclear phosphoprotein encoded by the 
TP53 gene [1] that is widely recognized to be the most 
important tumor suppressor in the cell. As a transcription 
factor, p53 responds to various stresses and activates 
multiple pathways including apoptosis, cell cycle arrest 
and DNA repair – hence its designation as the “guardian 
of the genome”. Recent studies reveal diverse additional 
functions of p53, including functions in cell stemness 
[2], epithelial–mesenchymal transition (EMT) and 
tumor metastasis [3, 4], tumor angiogenesis [5] and 
cellular senescence [6]. Given its critical role as a tumor 
suppressor, it is not surprising that TP53 is frequently 
mutated in cancer. Indeed, mutation of this gene occurs 
in over 50% of cancers [7], enabling malignant cells to 
escape wild-type p53-dependent growth inhibition and 
cell death.
The expression and activity of p53 is tightly 
regulated by, amongst other mechanisms, ubiquitination, 
phosphorylation and nuclear/cytoplasmic translocation. 
Two key negative regulators of p53 are MDM2 and 
MDM4. MDM2 is a specific E3 ligase for p53, promoting 
its polyubiquitination and subsequent degradation by the 
proteasome [8, 9]. MDM4, through its BOX1 domain, 
binds directly to p53 and inhibits its activity [10, 11]. 
MDM4 also interacts with MDM2 directly [12, 13] 
to enhance MDM2-mediated ubiquitination and p53 
degradation [14].
MicroRNAs (miRNAs), small non-coding RNAs 
that negatively regulate gene expression by binding to 
complementary sequences in their targets [15], have been 
shown to play an important role in the post-transcriptional 
regulation of p53. For example, several miRNAs and 
miRNA families directly regulate p53, including miR-125b 
[16], miR-504 [17], miR-380-5p [18], miR-25 and miR-
30d [19]. Other miRNAs can upregulate p53 expression 
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and activity by targeting MDM2 and MDM4. For example, 
miR-34a directly targets MDM4 by binding to a site in its 
open reading frame (ORF) [20, 21]. Interestingly, miR-34a 
is also a downstream target of p53 [22-24], and therefore 
represents a positive feedback loop for p53 through MDM4 
inhibition. Similarly, miR-605, miR-192 and miR-215, 
which directly target MDM2, are also downstream targets 
of p53 [25]. Moreover, miR-339-5p [26] and miR-661 
[27] also promote p53 activity and stabilities by targeting 
MDM2 and/or MDM4, while miR-122 [28], miR-885-
5p [29] and miR-542-3p stabilise p53 in cancer cells by 
disrupting MDM2-mediated p53 degradation [30].
MiR-766-3p (miR-766) is a microRNA residing 
within an intron of the SEP6 gene. Several studies 
indicated that miR-766 expression was highly expressed 
in cutaneous squamous cell carcinoma biopsies [31], lung 
adenocarcinoma (LUAD) [32] and acute promyelocytic 
leukemia cells [33]. In this present study, we analyzed 
small RNA sequencing data from The Cancer Genome 
Atlas (TCGA) and identified miR-766 as a putative post-
transcriptional regulator of p53. We demonstrated that 
miR-766 stabilised p53 by targeting the 3’UTR of MDM4, 
leading to repression of cell growth and cell cycle arrest 
in cancer cells and enhancing the p53 signalling pathway. 
Overall, our study indicates that miR-766 is a new and 
important regulator of p53-dependent tumor suppression.
RESULTS
MiR-766 induces wild-type p53 protein 
accumulation and cell growth repression
We analyzed small RNA deep sequencing data 
of breast cancer tumors expressing wild-type p53 (228 
tumors) or missense p53 (57 tumors) downloaded from 
TCGA. Compared to tumors with wild-type p53, miR-766 
was elevated in mutant p53 tumor samples (Supplementary 
Figure 1A). More data was collected from TCGA across 
different cancer types (including hepatocellular carcinoma, 
lung squamous cell carcinoma, lung adenocarcinoma, 
colon adenocarcinoma, stomach adenocarcinoma and 
ovarian serous cystadenocarcinoma), and a trend of 
increased miR-766 expression in p53 mutant groups was 
found (Supplementary Figure 1B). Given that highly 
expressed wild-type p53 induces cell proliferation arrest 
or cell programmed death, cancer cells tend to suppress 
factors that activate it. We hypothesized that the down-
regulation of miR-766 in wild-type p53 tumors compared 
to mutant p53 may indicate a potential connection between 
miR-766 and p53 function.
To test this hypothesis, we ectopically over-expressed 
miR-766 in a panel of wild-type p53 cancer cell lines 
derived from breast cancer, lung cancer and sarcoma 
(Supplementary Figure 2) to observe its effect on p53 
levels. In all cell lines examined, we observed increased 
p53 protein levels following transfection of miR-766 
mimic (Figure 1A). Conversely, inhibition of miR-766 
using an LNA inhibitor reduced p53 protein in SBC3 and 
U2OS cells, further supporting the concept that this miRNA 
maintains p53 expression (Figure 1B). To determine if these 
effects were transcriptional or post-transcriptional, p53 
mRNA was measured following miR-766 over-expression 
in MCF10A, SBC3 and U2OS cells. No significant change 
in p53 mRNA was observed (Supplementary Figure 3), 
suggesting that p53 protein levels were increased by miR-
766 at a post-transcriptional level.
We next asked whether the miR-766-mediated 
increase in p53 protein was associated with enhanced p53 
cellular activity. Cell proliferation assays demonstrated 
that the growth of MCF10A, SBC3 and U2OS cells was 
significantly suppressed after ectopic over-expression of 
miR-766 (Figure 1C). Moreover, using a colony formation 
assay, we found that miR-766 decreased clonogenicity in 
MCF10A, SBC3 and U2OS cells (Figure 1D). Conversely, 
inhibition of miR-766 using an LNA inhibitor increased 
cell proliferation and colony formation of SBC3 and 
U2OS cells (Figure 1E). A soft agar colony formation 
assay was used to further investigate the anti-growth 
capacity of miR-766. As shown in Figure 1F, the ability 
of SBC3 and U2OS cell lines to generate spheres was 
significantly impaired after miR-766 over expression 
in both S. Collectively, these data reveal that miR-766 
increases wild-type p53 levels, resulting in reduced cell 
proliferation and colony formation.
MiR-766 promotes G2/M arrest in U2OS and 
SBC3 cells
To further explore the biological function of miR-766, 
flow cytometry was used to analyze its impact on cell cycle 
regulation. We observed a significantly increased proportion of 
cells in G2 phase 48 hours after miR-766 mimic transfection in 
U2OS and SBC3 cells (Figure 2A). Specifically, the proportion 
of cells blocked at the G2/M checkpoint increased from 17.9% 
to 33.8% in U2OS cells and 8.6% to 18.1% in SBC3 cells. 
Conversely, a decrease of G2 phase cells was observed in 
U2OS (24.1% to 14.3%) and SBC3 (16.4% to 9.9%) cells 
after miR-766 inhibition (Figure 2B).
To detect molecular alterations in the p53 pathway 
associated with changes in miR-766 expression, we 
characterized the mRNA levels of GADD45A, SFN and 
GEST1 genes (as these genes are p53 downstream targets 
involved in cell cycle regulation) following transfection 
of miR-766 mimic. As expected, all of these genes were 
significantly induced by miR-766 (Figure 2C), which is 
consistent with observed increased expression of p53 and 
G2/M phase.
To explore the association between miR-766 and 
p53 signalling in clinical samples, we utilized gene set 
enrichment analysis (GSEA). By analysing lung cancer 
samples from TCGA, we identified a positive association 
between miR-766 expression and genes upregulated by 
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Figure 1: MiR-766 upregulates p53 expression and blocks cancer cell growth. (A) Whole protein lysates were collected 24 and 
48 hours following transfection with miR-766 mimic or a “scramble” control miRNA mimic. p53 protein levels were detected by Western 
blotting (β-Actin was used as a loading control). (B) Whole protein lysates were collected 24 and 48 hours following LNA miR-766 
inhibitor or LNA control transfection. p53 protein levels were detected by Western blotting (β-Actin was used as a loading control). (C) Cell 
proliferation was determined by Cell-TiterGlo Assay from in U2OS, SBC3 and MCF10A cells following transfection with miR-766 mimic 
or a “scramble” control miRNA mimic. (D) Colony formation assay was performed on U2OS, SBC3, MCF7 and MCF10A cells following 
transfection with miR-766 mimic or a “scramble” control miRNA mimic. (E) Cell proliferation was determined by Cell-TiterGlo Assay 
in SBC3 cells following transfection with LNA miR-766-inhibitor or LNA control. Colony formation assay was performed on SBC3 cells 
following transfection with LNA miR-766-inhibitor or LNA control. (F) Soft agar colony formation assay was performed using miR-766 
mimic transfected SBC3 and U2OS cells in 0.7%-0.3% agar gel and incubated for 3 weeks. For all assays, p values (* p<0.05, **p<0.01, 
*** p<0.001) were determined by Student’s t-test.
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p53 in 3 distinct gene sets, and a negative association 
between miR-766 and genes down-regulated by p53 in one 
gene set (Figure 2D). These associations further support 
the concept that miR-766 enhances p53 activity in cancer.
MDM4 is a direct target of miR-766
Since target genes of miRNAs are expected to be 
downregulated, we speculated that miR-766 may directly 
target one or more negative regulators of p53. The online 
miRNA target prediction tool miRDB.org lists 5 putative 
binding sites for miR-766 in the 3’UTR of MDM4 
mRNA (Figure 3A). To validate this potential interaction, 
sequences carrying the predicted miR-766 recognition 
sites were cloned downstream of luciferase and used for 
reporter assays. Sites 2, 3 and 4 were strongly repressed 
by miR-766, site 5 weakly, and site 1 was not regulated 
(Figure 3B). Having confirmed a direct interaction 
between miR-766 and sites in the MDM4 3’UTR, we 
subsequently transfected cells with miR-766 mimic and 
measured MDM4 expression. As shown in Figure 3C 
and 3D, miR-766 over-expression reduced both MDM4 
Figure 2: miR-766 is positively correlated with active p53 signalling. (A-B) Cell cycle profiles were analyzed through PI 
staining in U2OS and SBC3 48 hours after (A) miR-766 over-expression and (B) miR-766 inhibition. (C) Total RNA was collected from 
SBC3 and U2OS cells following transfection with miR-766 mimic or a “scramble” control miRNA mimic. GADD45A, SFN and GSTE1 
mRNA levels were detected by qRT-PCR (normalized using GAPDH). Results are the average of three independent experiments. p values 
(* p<0.05, *** p<0.001) were determined by Student’s t-test. (D) MiR-766 is positively correlated with p53 signalling in lung cancer, as 
determined by gene set enrichment analysis. The correlation between expression levels of miR-375 and 20,531 genes was calculated using 
matched miRNA and mRNA data from 102 lung tumors. Genes were subsequently ranked according to Pearson correlation coefficient (r) 
value (shown by a heat map), and GSEA (Preranked analysis) was implemented using the Broad Institute’s public GenePattern server, using 
default parameters.
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Figure 3: MDM4 is a direct target of miR-766. (A) Putative miR-766-binding sequence in the 3’UTR of MDM4 mRNA. 
(B) Luciferase reporter assays 48 h after transfection with miR-766 mimics and reporter plasmids. Results are the average of 3 independent 
experiments. p values (* p<0.05, *** p<0.001) were determined by determined by unpaired t tests. (C) MCF10A, U2OS, SBC cells 
were transfected with miR-766 mimic or LNA miR-766-inhibitor and control. Whole protein lysates were collected 24 and 48 hours after 
transfection and p53 and MDM4 protein levels were detected by Western blotting (β-Actin was used as a loading control). (D) Total RNA 
was collected after miR-766-mimic transfection in U2OS and SBC3 cells. MDM4 mRNA levels were detected by qRT-PCR (normalized 
using GAPDH). Results are the average of 3 independent experiments. p values (* p<0.05, *** p<0.001) were determined by Student’s 
t-test. (E-F) SBC3 and 16HBE (E) and H1299 (F) cells were transfected with miR-766 mimic and a scramble control. Whole protein lysates 
were collected 24, 48 and 72 hours after transfection and p53 and MDM4 protein levels were detected by Western blotting (β-Actin and 
a-tubulin were used as loading controls).
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protein and mRNA levels 48 hours in MCF10A, SBC3 
and U2OS cells. Conversely, miR-766 inhibition with an 
LNA increased MDM4 protein (Figure 3C). To confirm 
the specificity of MDM4 targeting by miR-766, an 
unrelated miRNA, miR-375, was used as an additional 
negative control (Supplementary Figure 4). Finally, to 
further validate the activity of miR-766, we assessed 
its effect on the expression of a previously reported 
target gene, BAX [33]: as expected, miR-766 caused a 
significant reduction of Bax protein (Supplementary 
Figure 5).
To further assess the relevance of the miR-766-
MDM4 interaction in p53 signalling, we employed the 
16HBE lung epithelial cell line, which expresses wild-type 
p53 but very low levels of MDM4 compared with SBC3 
(Figure 3E). Although MDM4 was down-regulated by 
miR-766 in this line, there was no effect on p53, which can 
be explained by the very low basal levels of MDM4, while 
p53 was strongly increased in SBC3 following MDM4 
inhibition. Considering the negative feedback regulation 
of the p53-MDM2-MDM4 axis [34], we also examined 
miR-766-mediated targeting of MDM4 in a p53-negative 
line, H1299, to exclude the possibility that the change in 
MDM4 after miR-766 over expression was a result of p53 
accumulation (Figure 3F). Although MDM4 protein was 
low in general in this model system, it was further reduced 
by miR-766 transfection, verifying the direct link between 
these two factors.
To validate the impact of MDM4 knockdown in our 
model systems, U2OS and SBC3 cells were transfected 
with MDM4 siRNA. Consistent with our hypothesis, 
knockdown of MDM4 (Figure 4A) pheno-copied miR-766 
over expression: more specifically, it induced significant 
cell growth repression (Figure 4B), decreased soft agar 
clonogenicity (Figure 4C) and caused an increase in G2/M 
phase cells (Figure 4D).
To further validate the biological relevance of 
the miR-766-MDM4-p53 regulatory pathway, a vector 
expressing the MDM4 cDNA without its 3’UTR was 
constructed. Since expression of MDM4 protein from this 
vector would be independent of miR-766, it was used in 
“rescue” experiments. Over-expression of MDM4 reversed 
both G2/M arrest (Figure 4E) and p53 accumulation 
(Figure 4F) induced by miR-766 over expression in SBC3 
cells. This experiment confirms that MDM4 is likely to 
be the key target by which miR-766 enhances the p53 
signalling pathway.
DISCUSSION
An increasing number of miRNAs have been 
recognized to participate in the post-transcriptional 
regulation of p53 and its downstream pathways. In this 
study, we have shown for the first time that miR-766 
enhances p53 levels and signalling activity by directly 
targeting the p53 repressor, MDM4. By targeting MDM4, 
miR-766 enhances p53-mediated cell cycle arrest and 
repression of proliferation.
Cell cycle regulation is one of the core functions 
of p53. By transactivating downstream targets of p53, 
including CDKN1A, GADD45A, SFN and GTSE1, p53 
induces cell cycle arrest, primarily at the G1/S and G2/M 
check points [35]. MiRNAs have been previously reported 
to participate in p53-related cell cycle regulation. In our 
study, GADD45A, SFN and GTSE1 were significantly 
elevated by miR-766. Given that GADD45A [36] and 
SFN [37] function as inhibitors of G2/M progression, and 
GTSE1 is a p53-inducible gene that specifically delays 
the G2/M transition, we hypothesize that these genes are 
involved in the observed cell cycle arrest mediated by 
miR-766 over-expression.
While a number of studies describing roles for miR-
766 in different cancer types have been published, overall 
its function in malignancy is poorly characterized. In acute 
promyelocytic leukemia cells, miR-766 was reported to 
be down-regulated following arsenic trioxide (As2O3) 
treatment, resulting in elevation of the miR-766 target BAX 
and enhanced cell apoptosis [33]. In contrast, our study 
shows miR-766 is a positive regulator of p53 via directly 
targeting MDM4, and participates in cell cycle regulation. 
Interestingly, the BAX gene is also a downstream target 
of p53 [38]. This raises the interesting possibility that 
a miR-766-p53-Bax axis may exist such that miR-766 
maintains p53-mediated cell cycle regulation while 
concomitantly suppressing Bax-induced cell death. MiR-
766 has been shown to be upregulated in colorectal cancer 
and to be associated with promotion of cell proliferation 
and anchorage-independent growth by targeting SOX6 
in the colorectal adenocarcinoma line SW480 [39]. The 
results from this study define oncogenic roles to miR-766, 
which contrasts with our findings. The frequency of p53 
mutations in colorectal cancer is over 50%, and the cell 
line SW480 is p53 mutant. We speculate that miR-766 
can function as a tumor suppressor in a wild-type p53 
environment but can switch to an oncomiR when p53 is 
inactivated by mutation.
There are previous reports showing increased 
miR-766 expression in cancers. MiR-766 was found 
to be significantly up-regulated in 7 pairs of cutaneous 
squamous cell carcinoma biopsies [31] and 372 lung 
adenocarcinoma cases correlating with late stage and 
poorer prognosis [32]. The status of p53 and MDM4 
was not specified in those studies but it is known that 
the frequency of p53 mutations is high in both cutaneous 
squamous cell carcinoma (40%-50%) [40] and lung 
adenocarcinoma (63%) [41]. This knowledge, in 
combination with our finding that miR-766 is elevated in 
p53-mutant cancers (Supplementary Figure 1) complicates 
the association between miR-766 and malignancy 
identified in the earlier studies of lung adenocarcinoma 
[32] and cutaneous squamous cell carcinoma [31]. We 
examined the association between miR-766 and cancer 
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Figure 4: MDM4 is a biologically relevant target of miR-766. (A-D) SBC3 and U2OS cells were transfected with MDM4 siRNA, 
(A) whole protein lysates were collected 48 hours after transfection, MDM4 protein levels were detected by Western blotting (a-tubulin 
used as loading control); (B) Cell proliferation was determined by Cell-TiterGlo Assay following transfection; (C) transfected SBC3 and 
U2OS cells were plated in 0.7%-0.3% soft agar and incubated for 3 weeks; (D) Cell cycle profiles were analyzed through PI staining 48 
hours after transfection. Results are the average of three independent experiments. p values (**P<0.01; *** p<0.001) were determined by 
Student’s t-test. (E) SBC3 cellswere co-transfected with miR-766 mimic and a MDM4 over-expression vector or a control vector. Cell cycle 
profiles were analyzed through PI staining 48 hours after transfection. Results are the average of three independent experiments. p values 
(**P<0.01; *** p<0.001) were determined by Student’s t-test. (F) Whole protein lysates were collected from cells 48 hours after transfection 
as described in E. p53 and MDM4 protein levels were detected by Western blotting (β-Actin was used as a loading control).
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specifically in wild-type p53 tumours of multiple cancer 
types. While miR-766 was upregulated in breast and liver, 
it was not significantly changed in stomach cancer and was 
down-regulated in lung adenocarcinoma (Supplementary 
Figure 7). With our new findings in mind, the links 
between miR-766 and malignancy, and hence its previous 
designation as an oncomiR [33, 39], are ambiguous.
Since miRNAs have multiple targets, their roles in 
normal biology and disease are highly context-dependent. 
Indeed, many examples exist where specific miRNAs 
have dichotomous functions in different tissues or disease 
states [42]. With this concept in mind, what our study does 
conclusively indicate is that p53 status will influence the 
biological functions of miR-766 in tumours. Specifically, 
miR-766 can target MDM4 and thereby act as a tumor 
suppressor when MDM4 levels are high, but fails to 
regulate p53 levels or activity in cells with low expression 
of MDM4. Thus, in contexts where MDM4 levels are low, 
or in mutant p53 tumors where the normal transactivation 
activities of p53 are compromised, miR-766 may potentially 
exhibit oncogenic behaviour. Having said that, we failed to 
observe any significant impact on either p53 level or cell 
proliferation after miR-766 over expression in p53 mutant 
cell lines (H2009 expressing p53R273L and MDA-MB-468 
expressing p53R273H) (Supplementary Figure 6).
MiR-766 was reported to increase in esophageal 
carcinoma cell lines following 5-fluorouracil treatment [43]. 
5-fluorouracil is known to induce the accumulation of p53 
and thereby activate p53 dependent pathways [44]. Thus, 
we speculate that in addition to the known mechanism 
of p53 stabalization via MDM2 due to its activation of 
DNA damage pathways, miR-766 is up-regulated and 
this also contributes to stabilization of p53 via modulation 
of MDM4. In normal cells, elevated miR-766 levels can 
provide an additional mechanism that contributes to the 
stabilization of p53 after external insults. However, in 
cancer, this function of miR-766 is absent where p53 is 
mutated or through disruption of other pathways, resulting 
in miR-766 engaging in alternative functions, some of 
which may be oncogenic. Based on these results, it is likely 
that high levels of miR-766 in the context of wild-type 
p53 may provide an approach for identifying cancers with 
greater sensitivity to DNA damaging agents.
In summary, our study is the first to identify miR-
766 as a novel p53 activator that functions by targeting 
MDM4 and thereby enhancing the p53 signalling axis. We 
propose that miR-766 could serve as a potential marker for 
MDM4 and wild-type p53 based cancer therapies such as 
MDM4 siRNA and 5-fluorouracil treatment.
MATERIALS AND METHODS
Cell lines and reagents
MCF10A, MCF7, HEK293T, MDA-MB468 and 
U2OS cell lines were purchased from the American Type 
Culture Collection (ATCC). Other sarcoma cell lines used 
were supplied by G. Hamilton (University of Vienna, 
Austria) (TC252) and P. Ambros (St. Anna Children’s 
Hospital, Austria) (STA-ET-1). SBC-3 and H2009 were 
kindly given as a gift from Dr. Sandra Hodge (University 
of Adelaide, Australia). SBC 3 was maintained in DMEM 
with 10% FBS, HEPES and PSG. H2009 was maintained 
in RPMI-1640 with 10% FBS. All other cell lines were 
cultured as previously described [45-47].
Reverse-transcription PCR (RT-PCR) and 
real-time RT-PCR
RNA extraction from cells was performed using 
the RNAeasy mini kit (Qiagen, Valencia, CA USA) 
and MIReasy mini kit (Qiagen). ND-1000 NanoDrop 
spectrometer (Thermo Scientific, Wilmington, DE USA) 
were used to measure RNA concentration. Total RNA 
and small RNA were reverse-transcribed into cDNA as 
previously described using Moloney Murine Leukaemia 
Virus (M-MLV) Reverse Transcriptase (Promega, Madison, 
WI USA) and random 6’mer primers (Promega) [47].
To determine Real-time PCR reactions were 
performed using IQ SYBR Green Supermix (BioRad) 
on a BioRad iCycler (BioRad) as previously described 
[45]. Primers used for Real-time PCR were listed in 
Supplementary Table 1. Relative expression levels of 
specific mRNAs were subsequently determined by the 
ΔΔCT method and normalized with GAPDH (Primers see 
Supplementary Table 1).
Vector construction
For luciferase assay, MDM4 3’UTR parts with miR-
766 binding sites were obtained by synthetic single chain 
oligo annealing (oligo sequences see Supplementary Table 
2), and were connected into psiCHECK2 dual-luciferase 
vector (Promega).
For MDM4 over expression, pENTR223.1 with 
MDM4 cDNA clone was purchased from Mybiosource. 
pcDNA3.2-DEST-MDM4 and control were constructed 
using pcDNA™3.2/GW/D-TOPO® Expression Kit from 
Raman Sharma (University of Adelaide, Australia) and 
pENTR223.1-MDM4.
Transient transfection
Asynchronously growing cells were seeded at 3 x 
105 cells/well in six-well plates or 1 x 105 cells/well in 
24-well plates. Transfection of cells with 50 nM mimic 
miR-766 (Genepharma, Shanghai, CN) or 50 nM LNA 
anti-miR (EXIQON, Denmak) or 100nM siRNA (Sigma 
Aldrich) was performed using Lipofectamine RNAiMAX 
(Invitrogen, CA, USA). Transfection of cells with 1ug/
mL with psiCHECK2 dual-luciferase reporter vectors 
or pcDNA3.2-DEST-MDM4 and control was performed 
using Lipofectamine 2000 (Invitrogen).
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Cell proliferation assay
Cells were plated at 1000 cells/well in 96-well 
plates 24 hours after transfection and were cultured for 
1, 2, 3, 4 and/or 5 days. On the indicated days, cells 
were incubated with CellTiter-Glo Luminescent Cell 
Viability Assay Kit (Promega) and fluorescence was 
measured by LUMIstar Galaxy luminometer (BMG 
Labtech).
Cell clonogenic assay
500 cells were placed in 6-well plates 24 hours after 
transfection, and cultured in complete medium for 10 days 
(MCF10A and SBC3) and 15 days (U2OS). Colonies were 
fixed with methanol, stained with 0.1% crystal violet, and 
counted.
Soft agar colony formation assay
15000 cells were mixed with 0.35% soft agar and 
placed in 6-well plates coated with 0.7% soft agar 24 
hours after transfection, and cultured for 3 weeks (SBC3) 
and 5 weeks (U2OS). Colonies were fixed with ethanol, 
stained with 0.1% crystal violet, and counted.
Cell cycle analysis
48 and 72 hours after transfections, cells were 
harvested and fixed as previously described for cell cycle 
analysis [48]. Fixed cells were stained with 100 μg/
mL RNase A (Sigma Aldrich) and 50 μg/mL propidium 
iodide solution (Sigma Aldrich) in PBS for 45 minutes at 
37°C. DNA content was determined by a FACSCalibur™ 
flow cytometer (BD, CA, USA). Cell cycle profiles were 
analyzed using WinMDI v2.8 software (Scripps Research 
Institute).
Western blot and antibodies
Western blot assay was performed as previously 
described [47]. Antibodies used include: mouse anti-p53 
DO-1 (Santa Cruz Biotechnology, Santa Cruz, CA), 
Rabbit anti-MDM4 (Bethyl Laboratories), mouse anti-
BAX (Invitrogen), mouse anti-a-tublin (Santa Cruz) and 
mouse anti-β-actin (Sigma Aldrich).
Luciferase assay
For the luciferase reporter assay, 293T cells were 
plated in a 24-well plate and then cotransfected with 50 
µM of either miR-766 mimic or negative control, and 1 
ug of psiCHECK2-MDM4-3’UTR-BS1, psiCHECK2-
MDM4-3’UTR-BS2, psiCHECK2-MDM4-3’UTR-BS3, 
psiCHECK2-MDM4-3’UTR-BS4 or psiCHECK2-
MDM4-3’UTR-BS5, using Lipofectamine 2000 
(Invitrogen). Cells were collected 48 h after transfection 
and fluorescence was meassured using the Dual-Luciferase 
Reporter Assay System (Promega). Both Renilla and 
Firefly luminescence were measured with a GloMax 20/20 
Luminometer (Promega). Renilla luciferase was used as 
an internal control for any differences in transfection and 
harvesting efficiencies. Transfections were performed in 
duplicate and repeated at least three times in independent 
experiments.
Gene set enrichment analysis
The Pearson correlation coefficient (r) between 
miR-766 and 20,501 genes was calculated using sample 
matched miRNA and mRNA expression profiles from 
102 wild-type p53 lung tumors (data was obtained from 
the TCGA data portal). Genes were subsequently ranked 
by r value. GSEA Preranked analysis was implemented 
using the Broad Institute’s public GenePattern server, 
using default parameters and 3 distinct p53-associated 
gene sets: the Kannan_TP53_Targets gene sets contain 
58 up-regulated and 24 down-regulated p53 gene targets; 
the Inga_TP53_Targets gene set contains 17 direct 
p53 targets that were verified to be strongly activated 
following p53 expression; the Hallmark p53 gene set 
covers a broader range of both direct and indirect targets 
of p53.
Statistical analysis
Data are presented as means ± SD from at least 
three independent experiments. Student’s t-test was 
performed using replicate values to compare between 
groups and indicate significance. Values of p<0.05 were 
considered statistically significant (as labeled as * in 
figures), while values of p<0.01 were labeled as ** and 
p<0,001 as ***.
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